Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05011058




Registration number
NCT05011058
Ethics application status
Date submitted
2/08/2021
Date registered
18/08/2021
Date last updated
31/07/2024

Titles & IDs
Public title
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Scientific title
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Secondary ID [1] 0 0
VT3996-202
Universal Trial Number (UTN)
Trial acronym
NAVAL-1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Epstein-Barr Virus Associated Lymphoproliferative Disorder 0 0
EBV-Related PTLD 0 0
EBV Related Non-Hodgkin's Lymphoma 0 0
EBV-Positive DLBCL, NOS 0 0
EBV Associated Lymphoma 0 0
EBV Related PTCL, NOS 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cardiovascular 0 0 0 0
Diseases of the vasculature and circulation including the lymphatic system
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Nanatinostat in combination with valganciclovir

Experimental: Nanatinostat with Valganciclovir - Patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week with valganciclovir 900 mg orally once daily.

Up to 10 PTCL patients will receive nanatinostat 20 mg orally once daily, days 1-4 per week.


Treatment: Drugs: Nanatinostat in combination with valganciclovir
Drug: Nanatinostat, 20 mg orally once daily, 4 days per week in 28 day cycles

Other name: VRx-3996

Drug: Valganciclovir, 900 mg orally once daily in 28 day cycles
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Objective response rate (ORR)
Timepoint [1] 0 0
Approximately 3 years
Secondary outcome [1] 0 0
Duration of response (DOR)
Timepoint [1] 0 0
Approximately 3 years
Secondary outcome [2] 0 0
Time to next anti-lymphoma treatment (TTNLT)
Timepoint [2] 0 0
Approximately 3 years
Secondary outcome [3] 0 0
Progression-free survival (PFS)
Timepoint [3] 0 0
Approximately 3 years
Secondary outcome [4] 0 0
Time to progression (TTP)
Timepoint [4] 0 0
Approximately 3 years
Secondary outcome [5] 0 0
Overall survival
Timepoint [5] 0 0
Approximately 3 years
Secondary outcome [6] 0 0
Incidence and severity of treatment-emergent adverse events
Timepoint [6] 0 0
Approximately 28 days following the last dose
Secondary outcome [7] 0 0
Pharmacokinetic parameter - time to maximum plasma concentration [tmax],
Timepoint [7] 0 0
Approximately 6 months following the end of Cycle 1 Day 1 (each cycle is 28 days)
Secondary outcome [8] 0 0
Pharmacokinetic parameter - maximum plasma concentration [Cmax]
Timepoint [8] 0 0
Approximately 6 months following the end of Cycle 1 Day 1 (each cycle is 28 days)
Secondary outcome [9] 0 0
Pharmacokinetic parameter - area under the plasma concentration-time curve [AUC]
Timepoint [9] 0 0
Approximately 6 months following the end of Cycle 1 Day 1 (each cycle is 28 days)

Eligibility
Key inclusion criteria
Key

* EBV+ DLBCL, NOS and PTCL, NOS, and AITL: Relapsed/refractory disease following 1 or more prior systemic therapy(ies) with curative intent.
* For EBV+ PTLD patients: Relapsed/refractory disease following 1 prior therapy and must have received at least 1 course of an anti-CD20 immunotherapy. For patients with EBV+ PTLD only, age 12 years and older and weighing greater than 40 kg (Adolescent, Adult, Older Adult) are allowed
* For other EBV+ relapsed/refractory lymphoma: Following at least 1 course of an anit-CD20 immunotherapy and at least 1 course of anthracycline-based chemotherapy (unless contraindicated)
* No available therapies in the opinion of the Investigator
* Not eligible for high-dose chemotherapy with allogeneic/autologous stem cell transplantation or CAR-T therapy
* Measurable disease per Cheson 2007
* ECOG performance status 0, 1, 2
* Adequate bone marrow function

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Presence or history of CNS involvement by lymphoma
* Systemic anticancer therapy or CAR-T within 21 days
* Antibody (anticancer) agents within 28 days
* Less than 60 days from prior autologous hematopoietic stem cell or solid organ transplant
* Less than 90 days from prior allogeneic transplant.
* Daily corticosteroids (=20 mg of prednisone or equivalent) within week prior to Cycle 1 Day 1
* Inability to take oral medication, malabsorption syndrome or any other gastrointestinal condition (nausea, diarrhea, vomiting) that may impact the absorption of nanatinostat and valganciclovir.
* Active infection requiring systemic therapy (excluding viral upper respiratory tract infections).

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/05/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/12/2026
Actual
Sample size
Target
140
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Box Hill Hospital - Melbourne
Recruitment hospital [2] 0 0
The Alfred Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
- Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Kentucky
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Montana
Country [10] 0 0
United States of America
State/province [10] 0 0
New Hampshire
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
South Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Texas
Country [18] 0 0
United States of America
State/province [18] 0 0
Utah
Country [19] 0 0
United States of America
State/province [19] 0 0
Washington
Country [20] 0 0
Brazil
State/province [20] 0 0
Joinville
Country [21] 0 0
Brazil
State/province [21] 0 0
Rio De Janeiro
Country [22] 0 0
Brazil
State/province [22] 0 0
Santo André
Country [23] 0 0
Brazil
State/province [23] 0 0
São Paulo
Country [24] 0 0
Canada
State/province [24] 0 0
Alberta
Country [25] 0 0
Canada
State/province [25] 0 0
British Columbia
Country [26] 0 0
Canada
State/province [26] 0 0
Ontario
Country [27] 0 0
Canada
State/province [27] 0 0
Quebec
Country [28] 0 0
France
State/province [28] 0 0
Aquitaine
Country [29] 0 0
France
State/province [29] 0 0
Ile-de-France
Country [30] 0 0
France
State/province [30] 0 0
Limousin
Country [31] 0 0
France
State/province [31] 0 0
Nouvelle-Aquitaine
Country [32] 0 0
France
State/province [32] 0 0
Pays De La Loire
Country [33] 0 0
France
State/province [33] 0 0
Provence Alpes Cote d'Azur
Country [34] 0 0
France
State/province [34] 0 0
Rhone-Alps
Country [35] 0 0
France
State/province [35] 0 0
Marseille
Country [36] 0 0
France
State/province [36] 0 0
Paris
Country [37] 0 0
Germany
State/province [37] 0 0
Bavaria
Country [38] 0 0
Germany
State/province [38] 0 0
Niedersachsen
Country [39] 0 0
Germany
State/province [39] 0 0
Nordrhein-Westfalen
Country [40] 0 0
Germany
State/province [40] 0 0
Saxony
Country [41] 0 0
Germany
State/province [41] 0 0
Bremen
Country [42] 0 0
Germany
State/province [42] 0 0
Halle
Country [43] 0 0
Germany
State/province [43] 0 0
Leipzig
Country [44] 0 0
Germany
State/province [44] 0 0
Mannheim
Country [45] 0 0
Hong Kong
State/province [45] 0 0
Hong Kong
Country [46] 0 0
Israel
State/province [46] 0 0
Jerusalem
Country [47] 0 0
Italy
State/province [47] 0 0
Foggia
Country [48] 0 0
Italy
State/province [48] 0 0
Milan
Country [49] 0 0
Italy
State/province [49] 0 0
Pordenone
Country [50] 0 0
Italy
State/province [50] 0 0
Bologna
Country [51] 0 0
Italy
State/province [51] 0 0
Brescia
Country [52] 0 0
Italy
State/province [52] 0 0
Milano
Country [53] 0 0
Italy
State/province [53] 0 0
Pavia
Country [54] 0 0
Italy
State/province [54] 0 0
Reggio Emilia
Country [55] 0 0
Italy
State/province [55] 0 0
Roma
Country [56] 0 0
Korea, Republic of
State/province [56] 0 0
Gyeongsangbugdo
Country [57] 0 0
Korea, Republic of
State/province [57] 0 0
Busan
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Daegu
Country [59] 0 0
Korea, Republic of
State/province [59] 0 0
Incheon
Country [60] 0 0
Korea, Republic of
State/province [60] 0 0
Seoul
Country [61] 0 0
Malaysia
State/province [61] 0 0
Kuala Lumpur
Country [62] 0 0
Malaysia
State/province [62] 0 0
Kuching
Country [63] 0 0
Singapore
State/province [63] 0 0
Singapore
Country [64] 0 0
Spain
State/province [64] 0 0
Barcelona
Country [65] 0 0
Spain
State/province [65] 0 0
Madrid
Country [66] 0 0
Taiwan
State/province [66] 0 0
Taipei
Country [67] 0 0
Taiwan
State/province [67] 0 0
Kaohsiung
Country [68] 0 0
Taiwan
State/province [68] 0 0
Taichung City
Country [69] 0 0
Taiwan
State/province [69] 0 0
Tainan
Country [70] 0 0
Taiwan
State/province [70] 0 0
Taipei City
Country [71] 0 0
Taiwan
State/province [71] 0 0
Taoyuan City
Country [72] 0 0
United Kingdom
State/province [72] 0 0
Liverpool
Country [73] 0 0
United Kingdom
State/province [73] 0 0
London
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Viracta Therapeutics, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas
Trial website
https://clinicaltrials.gov/study/NCT05011058
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Donald (D.K.) Strickland, MD
Address 0 0
Viracta Therapeutics
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Strait Hicklin
Address 0 0
Country 0 0
Phone 0 0
858-400-8470
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05011058